A Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas (CheckMate 436) NCT02581631
This is a signaling study to assess whether nivolumab in combination with brentuximab vedotin is safe and effective in certain subtypes of non-hodgkin lymphomas.
- Condition: Non-Hodgkin’s Disease
- Phase: I & II
- Enrollment: 96
- Start: December 2015
- Estimated Completion: December 2018
- Last verified: December 2016
- Last Updated: December 2016
Last Editorial review: December 13, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.